Why Is DEXCOM INC (DXCM) Stock Up Today?

DexCom Inc. (DXCM) surged 10.92% to $82.68 in Tuesday’s session, driven by strong second-quarter results and raised 2026 revenue guidance. The stock opened with an 8.2% gap up from the prior close and traded in a volatile range before settling near its high. Analysts from BTIG, Stifel, and Truist raised price targets following the earnings report, reflecting optimism about the company’s growth trajectory.

What Happened

DexCom reported adjusted earnings per share of $0.70, exceeding the $0.61 estimate, and revenue of $1.308 billion, beating the $1.29 billion forecast. The company also raised its full-year 2026 revenue guidance to a range of $5.18 billion to $5.25 billion. These results were highlighted in the earnings call and a presentation published by the company. The revised guidance reflects strong international growth and margin expansion, as well as progress in the rollout of its G7 15-Day product. Analysts responded by increasing their price targets, with Stifel raising its target to $95, Truist to $93, and BTIG to $90.

Retail traders and market participants reacted positively to the news, with social chatter on platforms like X highlighting the earnings beat and revenue guidance increase. Meanwhile, Benchmark and other firms maintained Buy ratings with updated price targets.

What The Data Shows

The stock opened at $80.62 and reached a high of $83.42 before the session low of $78.49. Trading volume was 1.1 million shares, which is 0.2 times the 3-month average. The stock closed at $82.35, near the high of the session. DexCom has a market cap of $28.9 billion and a P/E ratio of 31.9. Recent insider transactions include sales by executives totaling $7.3 million in the last 90 days.

What To Watch

DexCom has no scheduled earnings date for the near term, but investors will continue to monitor analyst coverage and guidance revisions. The stock remains within its 52-week range of $54.11 to $89.98 and is trading near the upper end of that range.